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M alignant melanoma is a malignant tumor gen-erating from melanocytes in the skin (termed 
‘malignant cutaneous melanoma’),  and it easily metas-
tasizes to lymph nodes,  the lungs,  brain,  and gastroin-
testinal tract,  resulting in poor prognosis [1-5].  Primary 
cutaneous malignant melanoma tends to metastasize to 
digestive organs such as the liver (68%),  small intestine 
(58%),  colon (22%),  stomach (20%),  duodenum (12%),  
rectum (5%),  esophagus (4%),  and anus (1%) [1].  In 
contrast,  a primary malignant gastrointestinal mela-
noma is quite rare,  even though the gastrointestinal 
tract has melanocytes.  A primary gastrointestinal 
malignant melanoma can arise at any site of the gastro-
intestinal tract,  such as the anorectal region (53.6%),  
pharyngeal cavity (32.8%),  esophagus (5.9%),  stomach 
(2.7%),  small intestine (2.3%),  gallbladder (1.4%),  and 
large intestine (0.9%) [1 , 5 , 6].  Primary colonic malig-
nant melanoma is particularly rare; there are only 37 
cases in the literature [7-21].
Advances in the basic research into melanoma have 
dramatically improved the prognosis of patients with 
malignant melanoma.  For example,  the recently intro-
duced therapeutic strategies for melanoma use targeted 
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Targeted therapies for malignant melanoma have improved patients’ prognoses.  A primary gastrointestinal 
malignant melanoma is very rare,  with no standard treatment strategy.  We treated a 78-year-old Japanese 
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treatments such as a BRAF inhibitor,  a MEK inhibitor,  
and immune checkpoint antibody-blockade therapy 
[22].  However,  due to the rarity of primary gastroin-
testinal malignant melanoma,  there is no standard 
treatment or therapeutic guidelines.  Here,  we report 
the case of an elderly female patient with malignant 
melanoma of the descending colon and gallbladder suc-
cessfully treated with immune checkpoint anti-
body-blockade therapy for > 4 years.
Case Presentation
A 78-year-old Japanese female with hypertension 
and hyperlipidemia was referred to our hospital for the 
examination of a tumor at the descending colon causing 
uncomfortable bowel distension and lower abdominal 
pain.  There were no significant dermatological findings.  
The results of blood examinations were normal except 
for the patient’s anemia.  The levels of carcinoembry-
onic antigen (CEA) and carbohydrate antigen 19-9 
(CA19-9) were unremarkable.  A colonoscopy was per-
formed,  and it demonstrated a 5-cm Type 1 mass at the 
descending colon,  occluding the vast majority of the 
lumen with necrotic tissue;  the mass was clinically 
suspicious for malignancy,  but it did not resemble con-
ventional colon cancer (Fig. 1A).
The lesion was biopsied,  and the histological find-
ings showed poorly differentiated adenocarcinoma.  
However,  the biopsy results led to the suspicion that it 
was a malignant tumor.  The pathologist suspected that 
the tumor could be a malignant lymphoma,  malignant 
melanoma,  or soft tissue sarcoma.  A computed tomog-
raphy (CT) scan showed that there were 2 large tumors 
at the descending colon and gallbladder,  and the tumor 
at the descending colon caused tumor-induced invagi-
nation and consequently bowel obstruction 
(Fig. 1C , D).
We classified the clinical stage of the primary colon 
cancer as cT3(SS) N0 M0 (Stage II) and a gallbladder 
tumor.  At the same time,  a multidisciplinary team was 
organized consisting of staff of our hospital’s depart-
ments of gastroenterological surgery,  gastroenterology,  
medical oncology,  and anesthesia and the perioperative 
management center for the design of the therapeutic 
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Fig. 1　 Clinical findings.  A,  Colonoscopy view of the descending colon showing the 5-cm mass with necrotic tissue at the surface,  
occluding the majority of the colonic lumen; B,  Barium X-ray examination demonstrating the mass at descending colon occluding the 
majority of the colon (arrowhead); C,  CT scan showing the 5-cm tumor at the descending colon (arrowhead).  Upper:  Vertical view.  
Lower:  Sagittal view; D,  CT scan showing the 4-cm tumor at the gallbladder (arrowhead).  Upper:  Vertical view.  Lower:  Sagittal 
view; E,  CT scan showing that there is no remarkable lymph node behind the pancreas head (upper) and a small lymph node at the medi-
astinum lesion before the first surgery (lower).
strategy.  We decided to perform a laparoscopic left 
hemicolectomy and cholecystectomy to treat the 
tumor-induced invagination and obstruction,  and to 
determine the precise diagnoses of the tumors of the 
descending colon and gallbladder.
The patient then underwent a laparoscopic left 
hemicolectomy and D3 lymphadenectomy with a colo- 
colonic anastomosis,  and a cholecystectomy.  The post-
operative course was unremarkable,  and the patient was 
discharged on postoperative day 14.  The surgical spec-
imen showed that descending colon had a 35-mm 
tumor and the gall bladder had a 40-mm tumor 
(Fig. 2A , C).  Hematoxylin and eosin (HE) staining of 
the descending colon tumor,  the gallbladder tumor,  
and lymph nodes in mesocolon of descending colon,  
revealed that the tumors were comprised of small,  
round,  monoclonal cells with a high nuclear/cytoplasm 
(N/C) ratio (Fig. 2B, D).
One of the 21 dissected lymph nodes was positive 
for metastasis.  The immunohistochemistry analysis 
showed that most of the cancer cells from the gallblad-
der tumor were positive for S100,  human melanocyte 
black (HMB)-45,  and melanoma antigen recognized by 
T-cell-1 (MART-1),  which are highly sensitive and spe-
cific for the diagnosis of melanoma (Fig. 3).  In contrast,  
most of the gallbladder tumor cells were negative for 
α-SMA and desmin (Fig. 3).  The histological findings 
from the gallbladder tumor revealed the same appear-
ance as the descending colon tumor.  We thus diagnosed 
these tumors as malignant melanoma,  but we were 
unable to determine which was the primary tumor 
(descending colon or gallbladder).
A PET/CT examination conducted 1 month post- 
surgery revealed the acceleration of glucose uptake in 
the lymph node behind the pancreas head and a medi-
astinum lesion (Fig. 4).  Therefore,  immune checkpoint 
antibody-blockade therapy using nivolumab (ONO 
pharmaceutical Co.,  LTD,  Osaka,  Japan) was adminis-
trated intravenously every 3 weeks.  PET/CT scans per-
formed after nine cycles of nivolumab demonstrated 
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Fig. 2　 Macroscopic and microscopic appearance of the primary tumors and metastatic lymph nodes.  A,  Macroscopic appearance of 
the tumor of the descending colon; B,  Representative images of hematoxylin-eosin (HE) staining of the tumor of the descending colon (left 
panels) and metastatic lymph node (right panels); C,  Macroscopic appearance of the gallbladder tumor; D,  Representative images of HE 
staining of the gallbladder tumor; D,  Representative images of HE staining of a metastatic lymph node behind the pancreas head.  Scale 
bars: =200 μm.






















Fig. 3　 IHC of the primary tumor at the gallbladder.  Representative images of S-100,  HMB-45,  MART-1,  α-SMA,  desmin,  and HE 
staining of tumor gallbladder tumor.  Scale bars: =200 μm.
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Fig. 4　 PET-CT shows the course of the metastatic lymph nodes during the nivolumab treatment.  A,  PET-CT showing the metastatic 
lymph node behind the pancreas head (arrowhead); B,  PET-CT showing the metastatic lymph node at the mediastinum lesion (arrowhead).
that (1) the lymph node behind the pancreas head had 
shrunk,  (2) the glucose uptake in the lymph node 
around the mediastinum lesion disappeared,  and (3) 
there was no other metastasis in the whole body 
(Fig. 4).
We decided to resect this lymph node behind the 
pancreas head since there was only one viable meta-
static site.  We performed a lymphadenectomy around 
the pancreas head with an open laparotomy.  The 
patient’s postoperative course was unremarkable,  she 
was discharged on postoperative day 14.  The histo-
pathological analysis showed the same microscopic 
appearance as the primary tumor.  Even though the 
treatment with nivolumab had reduced the lesion’s size 
and decreased the glucose uptake of the lymph node,  
most of the melanoma cells were viable,  resulting in 
grade 1a as the histological evaluation of the efficacy of 
nivolumab (Fig. 2E).
Nivolumab was restarted as adjuvant chemotherapy 
1 month after the second surgery.  CT scans have been 
conducted every 3 months and PET-CT has been per-
formed every year.  These modalities indicated that the 
lymph node in the mediastinum lesion has remained as 
a small nodule and has had no uptake of glucose,  and 
there has not been any other metastasis in the patient’s 
body (Fig. 4).  There were no adverse effects from the 
nivolumab treatment.
Discussion
We have reported a case in which a multidisci-
plinary treatment approach including surgical resection 
and immune checkpoint antibody-blockade therapy was 
effective for a very rare primary gastrointestinal mela-
noma with distant metastasis.  The clinical presentation 
of a primary gastrointestinal melanoma is not specific.  
It is sometimes difficult to distinguish a primary gastro-
intestinal melanoma from conventional gastrointestinal 
cancer based on the clinical findings [1 , 23].  It is there-
fore indispensable to analyze the tumor specimen with 
immunohistochemical stains in order to diagnose a 
primary gastrointestinal melanoma; S-100 is very sen-
sitive to melanoma,  and HMB-45 and MART1 are also 
highly specific to melanoma [24].  In our patient’s case,  
before the surgical resection of the primary tumors,  HE 
staining demonstrated that the tumors were comprised 
of small,  round,  monoclonal cells with a high N/C 
ratio,  suggesting diffuse large B-cell lymphoma (DLBL).  
Immunohistochemistry (IHC) showed that the patient’s 
tumor was positive for BCL6 and MUM1 (which are 
markers of DLBL),  but negative for CD3,  CD5,  CD10,  
CD20,  CD30,  CD38,  CD79a,  CD138 (markers of 
hematopoietic cells).  The IHC also showed that the 
patient’s tumor was strongly positive for S-100.
There are three other tumors with overlapping clini-
cal features: gastrointestinal stromal tumor (GIST),  
epithelioid malignant peripheral nerve sheath tumor,  
and clear cell sarcoma (CCS) [1 , 25].  GISTs are some-
times is positive for S-100,  our patient’s tumor was 
strongly positive for HMB-45 and MART1 [26 , 27].  
Epithelioid malignant peripheral nerve sheath tumor 
also is positive for S-100,  but it has areas of necrosis and 
a larger vascularity ,  unlike malignant melanomas [27].  
CCS is a rare primary soft tissue sarcoma with melanin,  
and it is very rare in the gastrointestinal tract [27-32].  A 
primary soft tissue CCS can be positive for S-100,  
HMB45,  and MART-1,  but a primary gastrointestinal 
CCS can be negative for HMB45 and MART-1 [30-32].  
We thus diagnosed these tumors as primary gastroin-
testinal malignant melanoma.  Moreover,  it was 
recently reported that the expression of SOX10 or the 
existence of EWSR1-CREB1 or EWSR1-ATF1 fusion 
genes is useful to diagnose CCS [33-35].  We further 
checked EWSR1-ATF1 fusion genes by reverse tran-
scriptional polymerase chain reaction (RT-PCR).  
RT-PCR showed that this patient did not have EWSR1-
ATF1 fusion genes (Fig. 5).  Therefore,  we thus diag-
nosed these tumors as primary gastrointestinal malig-






Fig. 5　 EWSR1-ATF1 fusion genes.  Representative images of 
EWSR1-ATF1 fusion genes by reverse transcriptional polymerase 
chain reaction (RT-PCR).
nant melanoma at that time.  However,  in the present 
case it was not possible to determine whether the tumor 
was primarily generated from the descending colon or 
the gallbladder.
Ozdemir proposed criteria to differentiate primary 
bronchial melanoma from secondary melanoma:  
(1) the lesion must be solitary in the surgical specimen,  
(2) there must be no previously excised skin melanoma,  
(3) no previous or concurrent ocular tumor is present,  
(4) the morphology must be compatible with that of a 
primary tumor,  (5) there must be no other demonstra-
ble melanoma at the time of surgical exploration,  and 
(6) the findings should be confirmed by a careful 
autopsy for patients who succumb to the disease [36].  
In our patient’s case,  surgical resection was necessary to 
treat the tumor-induced invagination and obstruction,  
diagnose the colon and gallbladder tumors,  and estab-
lish the further therapeutic strategy.  Moreover,  endo-
scopic surgery was feasible for this patient [36 , 37 , 39].  
We thus performed a laparoscopic left hemicolectomy 
and cholecystectomy (less invasively than an open lapa-
rotomy),  and the patient could therefore receive 
immune checkpoint antibody-blockade therapy within 
1 month after the surgery.  However,  the lymph node 
lesions recurred just 1 month after the surgical resection 
of the primary tumor.
Targeted therapy is the most promising chemother-
apy regimen for advanced melanoma,  as such therapy 
has markedly improved the survival outcome of mela-
noma.  Targeted therapy may be comprised of BRAF 
and MEK inhibitors (dabrafenib + trametinib,  vemu-
rafenib + cobimetinib,  or encorafenib + binimetinib),  
anti-programmed death agent-1 (PD-1),  or nivolumab,  
in combination with anti-cytotoxic T-lymphocyte asso-
ciated antigen 4 (CTLA-4),  or ipilimumab [22].  Several 
randomized control trials have confirmed that mono-
therapy or combination therapy with a BRAF inhibitor 
and MEK inhibitor are effective for advanced mela-
noma.  Combination therapy with a BRAF inhibitor and 
MEK inhibitor provided a > 60% response rate and 
22.3-33.6 months as the median overall survival (OS) 
[22].
Nivolumab monotherapy resulted in a median OS of 
36.9 months and a 5-year OS rate at 44% [22].  
Combination therapy of nivolumab + ipilimumab also 
provided a median OS of > 60 months,  and the 5-year 
OS rate was 52% [22].  Immune checkpoint antibody- 
blockade therapy has thus improved the long-term 
overall survival of patients with advanced melanoma.  
In our patient,  the IHC results demonstrated that the 
primary tumors of the gallbladder and descending 
colon were positive for PD-L1 (Fig. 6).  We thus admin-
istered nivolumab after the first surgery [22].  
Nivolumab reduced the size of the lymph node behind 
the pancreas head and decreased the uptake of glucose,  
and it also diminished the lymph node at the mediasti-
num lesion.  However,  the H.E.  stain of the lymph 
node behind the pancreas head (resected by the second 














Fig. 6　PD-L1.  Representative images of PD-L1 staining of the tumors of the gallbladder and descending colon.  Arrowheads indicate 
PD-L1 positive cancer cells.  Scale bars: =200 μm.
surgery) demonstrated that it had viable melanoma 
cells,  and the efficacy of the nivolumab was grade 1A.  
In contrast,  the lymph node at the mediastinum lesion 
has remained small and does not take up glucose at 4 
years after the start of nivolumab treatment.  These find-
ings suggest that immune checkpoint antibody-block-
ade therapy is not always completely effective for a pri-
mary gastrointestinal malignant melanoma,  and thus 
the surgical resection of a chemoresistant melanoma 
should be performed if possible.  Our patient’s case 
demonstrates that a combination of radical resection 
and adjuvant immune checkpoint antibody-blockade 
therapy is a promising strategy against primary gastro-
intestinal malignant melanoma.
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